BORIS knockdown in colorectal cancer cells HCT116 and Caco-2

BORIS expresses abnormally in colorectal cancer cells. Both the expression and the copy number of BORIS are remarkably higher in colorectal cancer cells than in normal colon or rectal cells. BORIS is potential diagnosis, prognosis or therapeutic target for colorectal cancer. To expand our view of the signaling pathway related with BORIS, altered gene expression by BORIS knockdown was assessed by microarray assay. To study the gene regulation by BORIS knockdown, microarray assay was applied to screen the gene expression regulated by BORIS siRNA in colorectal cancer cells HCT116 and Caco-2 HCT116 and Caco-2 cells were silenced by siRNA of BORIS for 3 days and extracted for the RNA. Silenced samples and the controls were compared to screen for gene expression difference by Affymetrix PrimeView human gene expression array.